Ascendis Pharma A/s revenue

Ascendis Pharma A/s's revenue was $814m in fiscal 2025, up 106.9% on the year before. Since fiscal 2015 ($9.0m) it has grown at a compound 56.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascendis Pharma A/s: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	9	5	2	13	15	8	9	54	288	393	814
Growth on the year before	—	−43.4%	−66.1%	+623.2%	+19.7%	−47.0%	+16.0%	+485.9%	+435.2%	+36.4%	+106.9%
Gross profit	—	—	—	—	15	8	5	41	240	346	707
Gross margin	—	—	—	—	100.0%	100.0%	54.7%	76.3%	83.4%	87.8%	86.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Ascendis Pharma A/s	$814m	106.9%	—
Telix Pharmaceuticals Ltd	$804m	55.6%	—
TG Therapeutics, Inc.	$800m	76.1%	221.5%
Ionis Pharmaceuticals Inc	$874m	-7.4%	11.5%
Ultragenyx Pharmaceutical Inc.	$717m	17.5%	21.2%
Biocryst Pharmaceuticals Inc	$941m	68.7%	45.3%

Compare with peers

Head to head: ASND vs TLX ASND vs TGTX ASND vs IONS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascendis Pharma A/s's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascendis Pharma A/s.